Thefluoroquinolones in general. and particularly enoxacin. show great promise in the treatment of urinary tract infection. Orally administered enoxacin achieves high concentrations in the serum and urine as well as in prostate tissue. kidney and perirenal fat and muscle. These concentrations are generally in excess of the minimum inhibitory concentrations (MIC) for 95% of the common uropathogens. including Escherichia coli. Pseudomonas aeruginosa. Klebsiella spp .. Proteus spp .. Enterobacter spp .. Serratia marcescens and Staphylococcus saprophyticus. In comparative clinical trials. treatment with oral enoxacin has achieved satisfactory clinical results (symptoms improved or absent) in 67 to 96% of patients and satisfactory bacteriological results « 10 4 colony count of the original bacteria) in 77 to 98% of patients. Clinical cure or improvement occurred in 94 to 100% of patients in uncontrolled trials. with corresponding satisfactory bacteriological results of82 to 100%. In a number ofstudies of patients with difJicult-to-treat infections. satisfactory clinical results were achieved in 92 to 100% o/patients and satisfactory bacteriological results in 89 to 100% of patients.Antibiotic treatment of urinary tract infections presents problems, as in vitro bacterial susceptibility often correlates poorly with clinical results. Achievement of a bacterial inhibitory concentration of drug at the site of infection is essential for cure and probably more important than the plasma concentration. This is of even greater importance in difficult-to-treat infections such as prostatitis and pyelonephritis, in which bacteria tend to be more 'deeply rooted'. In addition, adequate tissue concentrations in areas such as the prostate and kidneys and in surrounding tissues such as fat and muscle are important in preventing infections associated with urological and renal surgery. spectrum quinolone antibiotic, in the treatment of urinary tract infections. As with other quinolones, enoxacin provides excellent coverage of pathogens most often found in urinary tract infections. In addition, the extensive tissue distribution of enoxacin results in concentrations that exceed MIC levels for most uropathogens.